CAR-T's Geography Problem: Why Approval Doesn't Equal Access
核心洞察
Geographic distance from a qualified treatment centre is one of the strongest predictors of whether an eligible patient receives CAR-T therapy, according to research published in Blood Advances.
Despite six CAR-T products receiving EMA marketing authorisation across 15 haematologic malignancies (搜索), several Eastern European nations have yet to report any commercial CAR-T use.
An analysis of G7 countries showed France and Germany funded 92% of CAR-T indications assessed, while England funded only 50% and Australia just 33%.
When Sam Neill announced he had received CAR-T cell therapy (搜索) and was in remission, the coverage was celebratory. A beloved actor. A remarkable outcome. But buried in that story was a detail worth sitting with: Neill accessed treatment through a clinical trial. He didn't pay the privately listed price of over $400,000. He was in the right place, at the right time, with the right referral. Most patients aren't.
That gap — between what CAR-T can do and who can actually get it — is the defining challenge of this field right now. And it's not a scientific problem. The science is working. The access model isn't.
Approved is not the same as accessible
Several CAR-T therapies have received regulatory approval in major markets. On paper, they exist. In practice, for a significant portion of eligible patients, they remain out of reach.
Research published in Blood Advances has consistently shown that geographic distance from a qualified treatment centre is one of the strongest predictors of whether an eligible patient receives CAR-T therapy at all. It's not biology. It's not clinical ineligibility. It's location. It's whether the oncologist knew the programme existed. It's whether the hospital had a referral relationship. It's whether the manufacturing slot was available in time.
CAR-T is not like filling a prescription. It requires a coordinated system: cell collection, vector supply, cell engineering, quality control, cold-chain logistics, clinical delivery, and intensive patient monitoring. Each one of those steps is a potential point of failure. And the current infrastructure was built to serve a relatively small number of patients at a relatively small number of highly specialised centres.
That was the right model to get the first generation of therapies approved. It is insufficient to get them to the broader patient population that would benefit.
The European paradox: approval without availability
Six CAR-T products have been granted marketing authorisation by the European Medicines Agency (搜索) (EMA) across the European Economic Area, collectively covering 15 haematologic malignancies (搜索) — a notable regulatory achievement. However, the current state of CAR-T therapies presents a paradox, as many patients across member states and hospital settings still cannot access these treatments.
Data from the European Society for Blood and Marrow Transplantation (EBMT) registry show over 10,000 CAR-T infusions across more than 600 centres in 60 countries as of September 2024, with activity concentrated largely in Western Europe. In contrast, several Eastern European nations have yet to report any commercial CAR-T use.
A cross-country analysis showed that, despite EMA authorisation, CAR-T therapies had not been introduced in all European countries. Latvia, Hungary and Malta offered only limited or no access to these treatments, and Norway was unable to provide certain approved products domestically.
HTA fragmentation drives geographic inequity
National health technology assessment (HTA) bodies independently assess clinical and economic value for therapies, each using different methodological frameworks, cost-effectiveness thresholds and budget-impact criteria. The result is a fragmented landscape: the same product may be reimbursed and integrated into clinical practice in one country, restricted to a narrow patient subset in another, pending assessment for years in a third and effectively unavailable in a fourth.
An analysis of reimbursement decisions by HTA bodies across G7 countries showed significant heterogeneity. France and Germany recommended funding for 92% of CAR-T indications assessed, while England funded only 50% and Australia just 33%. Such variation illustrates how the same EMA-approved evidence base can yield markedly different coverage outcomes depending on the national HTA framework applied.
With costs often exceeding €350,000 per patient per dose, disparities in access constitute a bureaucratic challenge and a significant issue of clinical equity. For patients with relapsed or refractory haematologic malignancies (搜索), whose survival may be measured in months, delays in access have direct consequences on outcomes.
Manufacturing is a patient access issue
The industry tends to treat manufacturing as a back-end operational concern. For advanced therapies, it isn't. In cell and gene therapy, manufacturing determines access. It shapes cost, turnaround time, which sites can participate, and ultimately which patients can be reached.
Lentiviral vectors (搜索) are critical raw materials for a large proportion of CAR-T and other cell therapy programmes. When vector supply is constrained, expensive, or difficult to customise, it creates a bottleneck that stalls development long before a therapy ever reaches a patient. For academic medical centres or smaller developers working outside major pharma infrastructure, that bottleneck can end a programme entirely.
The field needs to shift from industrialisation to operationalisation — building systems that are not just scientifically rigorous, but practically transferable: standardised, reproducible, and deployable closer to where patients are. This means treating technology transfer as an early design requirement and taking point-of-care and near-patient manufacturing seriously as a path toward broader reach.
The information gap compounds the access gap
The most consequential conversations in cell and gene therapy — about manufacturing advances, lower-cost vector supply, new trial designs, and emerging access pathways — are largely happening in closed industry settings. The developers, manufacturers, investors, and those connected with regulatory bodies in the room understand what is changing. The oncologist treating an eligible patient three states away does not.
That information asymmetry has direct clinical consequences. If a physician doesn't know a trial is open, the patient never gets referred. If an academic medical centre doesn't know that lower-cost manufacturing infrastructure now exists, a programme that could launch doesn't. With over 3,200 cell and gene therapy trials currently underway worldwide, and the FDA having introduced a new bespoke gene therapy approval pathway earlier this year, the pace of change is accelerating faster than the information is spreading.
European policy responses
The European Union has recognised these disparities. Proposed reforms to pharmaceutical legislation aim to incentivise marketing authorisation holders to launch products across all member states, rather than limiting launches to the largest markets, by offering extended data protection periods.
In parallel, the joint clinical assessment framework introduced under the EU HTA Regulation, effective for ATMPs from January 2025, aims to harmonise clinical evidence reviews, reduce duplication and establish a shared foundation to facilitate more efficient national pricing and reimbursement negotiations.
Outcomes-based managed entry agreements (OBMEAs) have been adopted in several European countries to address the cost and evidentiary uncertainty of CAR-T therapies. Italy and Spain employ individual performance-based agreements that link payment to patient response, while Belgium, England and France utilise population-based agreements to enable access and generate the real-world evidence required for re-appraisal.
Hospital pharmacists: the critical bridge
At the hospital level, pharmacists play a critical but often under-recognised role as facilitators of access. Traditionally associated with operational responsibilities — coordinating leukapheresis, cold-chain logistics, product release and toxicity management — their role increasingly encompasses strategic and governance domains.
Pharmacists in established CAR-T centres contribute to patient selection in line with reimbursement criteria, design governance frameworks that link clinical eligibility to budget approval, and manage the interface between EMA approval, hospital financing and patient care. The European Association of Hospital Pharmacists (搜索) (EAHP) advocates that hospital pharmacists participate in HTA bodies at both national and regional levels and serve as advisory experts in central price negotiations.
As CAR-T expands into autoimmune disease, infectious disease, and rare disease — some of which carry larger and more geographically distributed patient populations than the haematologic cancers that established the field — the pressure on the access model will intensify. A system designed for a few thousand patients a year at elite academic centres will not serve what this field is becoming.
Closing the access gap requires a deliberate effort on several fronts simultaneously: lower-cost vector supply that doesn't require large-pharma infrastructure to access; manufacturing workflows designed from the start for technology transfer; clinical and regulatory education that reaches community oncologists, not just academic specialists; reimbursement models built for the actual cost structure of advanced therapies; and connectivity between developers, clinicians, payers, patient advocates, and health systems that do not currently exist at scale.